• Publications
  • Influence
Toward a more accurate estimate of the prevalence of hepatitis C in the United States
Data from the 2003‐2010 National Health and Nutrition Examination Survey (NHANES) indicate that about 3.6 million people in the United States have antibodies to the hepatitis C virus, of whom 2.7Expand
  • 307
  • 18
  • PDF
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Highly effective (cure rate >90%), once-daily, oral interferon-free treatments with minimal adverse effects are now available for hepatitis C virus (HCV) infection. Worldwide, an estimated 80 to 150Expand
  • 334
  • 15
  • PDF
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.
Chronic hepatitis C virus (HCV) infection has become a major threat to the survival of human immunodeficiency virus (HIV)-infected persons in areas where antiretroviral therapy is available. InExpand
  • 142
  • 8
  • PDF
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the InfectiousExpand
  • 246
  • 5
  • PDF
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
BACKGROUND Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID.Expand
  • 127
  • 4
  • PDF
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group isExpand
  • 62
  • 4
Viral hepatitis and the Global Burden of Disease: a need to regroup
The publication of the updated Global Burden of Disease (GBD) [1,2] provides a broad overview of the challenges to global health. As with the previous surveys [3], it is likely that over the comingExpand
  • 101
  • 4
  • PDF
Review article: adherence to medication for chronic hepatitis C – building on the model of human immunodeficiency virus antiretroviral adherence research
Background  Treatment of hepatitis C virus (HCV) infection with pegylated interferon/ribavirin achieves sustained virological response in up to 56% of HCV mono‐infected patients and 40% of HCV/humanExpand
  • 57
  • 4
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemicsExpand
  • 181
  • 3
  • PDF
A path to eradication of hepatitis C in low- and middle-income countries.
We are entering a new era in the treatment of hepatitis C virus (HCV) infection and almost all patient groups in high-income countries have the potential to be cured with all-oral, highly potentExpand
  • 72
  • 3
  • PDF
...
1
2
3
4
5
...